Clinical Trials · NCT07700030

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

Not Yet RecruitingN/ATirzepatide (Investigational)
Phase
N/A
Recruitment status
Not Yet Recruiting
Sponsor
NYU Langone Health
Enrollment
32
Start date
Jul 2026
Locations
1 site, United States
Primary endpoint
Changes in lean Skeletal Muscle Mass (SMM) quadriceps
View Tirzepatide compound reference